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Background: The antimetabolite 6-thioguanine (6-TG) has been used to treat both human and canine lymphoid
malignancies. 6-TG has been shown to be epigenetically active as a demethylating agent in a human lymphoma
cell line, causing downregulation of DNA methyltransferase 1 (DNMT1) through ubiquitin-targeted degradation.
Zebularine (Zeb), a similar cytidine analog, also has demethylating activity as well as oral bioavailability. The hypothesis
of the present study was that 6-TG and Zeb would cause downregulation of DNMT1 and globally demethylate
the genomic DNA of canine lymphoma cells. The secondary hypothesis was that these agents would cause a
dose-dependent decrease in cell proliferation in canine lymphoma cells. Canine CLGL-90 malignant T cells and
CLL 17–7 cells were incubated in modified RPMI media. They were treated with 6-TG, Zeb, or control media at
biologically relevant concentrations.
Results: Following treatment with each agent, DNMT1 protein and global DNA methylation were significantly
decreased. A dose-dependent decrease in cell survival was also observed, with apoptosis being the primary mode
of cell death in the CLGL-90 cell line.
Conclusions: These results confirm the demethylating action of 6-TG and Zeb in canine cells which is similar to
that shown in human cell lines. Confirmation of this mechanism supports the clinical application of these compounds
as demethylating drugs in veterinary patients.
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Lymphoma is the most commonly diagnosed hemo-
lymphatic neoplasm of the dog [1]. Little progress has
been made in remission and overall survival duration in
the last few decades. Treatment involves cytotoxic chemo-
therapy with cyclophosphamide, doxorubicin, vincristine,
prednisone (CHOP) protocols [2]. Despite an over 90%
remission rate, almost all dogs relapse and eventually
become resistant to cytotoxic chemotherapy drugs. Rescue
protocols have been suboptimal, with median remission
durations ranging between 40 and 60 days after initiation
[3-7]. Recent work in human non-Hodgkin lymphoma
(nHL), the group of diseases most similar to canine* Correspondence: bryanjn@missouri.edu
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unless otherwise stated.lymphoma, has identified multiple epigenetic mecha-
nisms that could affect phenotype, aggressiveness, and
response to therapy [8-10].
Demethylating agents have previously been used for
human and canine hematopoietic malignancies [11-15],
with approval of 5-aza-2'-deoxycytidine (decitabine) for
human myelodysplastic syndrome and acute and chronic
myelogenous leukemia [16]. Research in canine lymph-
oma has also identified epigenetic alterations, speci-
fically methylation changes, associated with the neoplastic
phenotype [17-19]. The protein family responsible for
genomic methylation is a group of DNA methyltransfer-
ases (DNMTs); the specific maintenance methyltransferase
protein in mammals is DNMT1 [20]. A recent human
study showed that the drug 6-thioguanine (6-TG), a
well-described antimetabolite agent, caused genomic
demethylation by reduction of DNMT1 protein throughLtd. This is an Open Access article distributed under the terms of the Creative
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drug has a known safety profile in dogs [11,12], it was
selected for in vitro evaluation of its effect on global
methylation on canine lymphoma cell lines. Zebularine
(Zeb), a similar antimetabolite, also has been used
in vitro and in vivo [22-24] and has recently been shown
to be safe in the dog [C. Fulkerson, personal communi-
cation]. This led to similar interest in the compound for
its demethylating mechanism of action. This drug was
selected as a known demethylating comparator to the
6-TG. The hypotheses of these studies were that 6-TG
and Zeb would reduce DNMT1 protein, leading to a
decrease in global DNA methylation following exposure.
The secondary hypothesis was that the drugs would
decrease cell proliferation and induce apoptosis.
Methods
Cell culture
Two cell lines, a canine large T cell leukemia line CLGL-
90 and a canine B cell line CLL 17–7 [25] were grown in
custom RPMI media containing 1 mM sodium pyruvate,
10 mM HEPES, 2 mM L-glutamine, 0.4 mg/mL genta-
micin, supplemented with 10% fetal bovine serum, and
maintained at 37°C in a 5% CO2 air atmosphere. Cells
were separated and placed into 6-well plates containing
the same media. Initial experiments to monitor dose-
relationship and cell survival between 6-TG (Sigma-
Aldrich, St. Louis, MO) and Zeb (Zeb, Sigma-Aldrich,
St. Louis, MO) were performed by dilution in PBS to
yield final drug concentrations of 1.5, 3.0, and 6.0 μM
[21] and 50, 100, and 200 μM respectively [22]. These
biologically relevant concentrations are reported to be
achievable in vivo [23,26]. Cells were incubated for
24 hours, mixed, and half of the cells and culture media
were collected. Cells were centrifuged and the cell pellet
was collected for DNMT1 and methylation analysis. The
RPMI media was added to resuspend the remaining
cells, and the previously dosed concentrations of 6-TG
and Zeb were again added. The cells were again incu-
bated for another 24 hours. A final collection was taken
at 48 hours. Both 6-TG and Zeb were stored at −20°C
after reconstitution for future experiments.
DNMT1 western blot analysis
Protein was extracted from the same samples using MPER
reagent (Thermo Fisher). Protein concentrations were
measured (Nanodrop spectrophotometer) and samples
were stored in −20°C. Equal amounts of protein (approxi-
mately 30 ug) extracted from the cell lines were separated
by SDS–PAGE and blotted onto a PVDF membrane
as described previously [21]. Membranes were blocked
in 5% skimmed milk/Tris-buffered saline (TBS) for 1 h
at room temperature. After washing with 1 × TBS
the membrane was further incubated with DNMT-1primary antibody (#5119; 700 μg/ml; 1:500) (Cell Signaling
Technologies) and goat anti-rabbit secondary antibody
(#7074;65 μg/ml;1:5000) (Cell Signaling Technologies).
After evaluation via chemiluminescence (Kodak Image
Station), membranes were stripped with antibody strip-
ping buffer (Tris–HCl pH 6.8 with 2% SDS) containing
mercaptoethanol. The blots were re-probed with anti-
body against Beta-actin (#4970; 21 μg/ml; 1:1000) (Cell
Signaling Technologies), which served as a loading
control. Relative intensity was evaluated using ImageJ
(National Institutes of Health) to compare the intensity
of each DNMT1 band to the loading Beta-actin band.
Restriction landmark genomic scanning
DNA was extracted using a DNA extraction kit (DNeasy,
Qiagen). DNA concentrations were measured (Nano-
drop, Thermo-Scientific) and samples were immediately
used or stored at −20°C. Global methylation was analyzed
using restriction landmark genomic scanning (RLGS) as
previously described [17]. RLGS produces varying lengths
of DNA fragments dependent upon cytosine methyla-
tion status. Samples were incubated with either HpaII
or MspI. HpaII is unable to cleave DNA at its restriction
site (CCGG) when cytosine is methylated, as it is a
methylation-sensitive restriction endonuclease. However,
its isochizomer MspI is able to cleave the restriction site
regardless of cytosine methylation status. As DNA be-
comes hypomethylated, HpaII cleaves the strands more
completely, resulting in smaller restriction fragments. This
results in a change in intensity of the bands on DNA gel
electrophoresis optical analysis. DNA (200 ng) was incu-
bated with HpaII (New England BioLabs) or MspI (New
England BioLabs) along with supplied NE Buffer and
nuclease-free water for one hour at 37°C. After incubation,
samples were electrophoresed on a 1% agarose gel at
approximately 100 V/h. Comparison of the restriction
enzymes’ (HpaII vs. MspI) banding patterns was used to
determine alterations in the global methylation status of
the DNA. Methylation score values (MSVs) were calcu-
lated for the samples [17]. The gel was photographed
(UV Doc Station) and fragments in the 2.0-2.3 kb were
analyzed using ImageJ. Measurements of the intensity
of fragments were compared to background and MSVs
were calculated using the following equation:
MSV ¼ DensityHpaII− DensityBackground
DensityMspI− DensityBackground
Cell survival analysis
CLGL-90 cells [25] were grown as described. Manual-
count cell proliferation assays were performed. Cells
were treated with increasing concentration of 6-TG (0, 1.5,
3.0, and 6.0 uM) and Zeb (with 0, 50, 100, and 200 uM) at
24 and 48 hours in replicates of three [21-24]. Cells were
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Scientific, Horsham, PA), with four grids being counted.
An average of the four grids was calculated. Cells were
diluted with Trypan Blue vital stain and the viable
fraction was recorded at each time point. Dilution was
appropriate to yield a minimum 100-cell count at each
counting. Three replicates allow detection of a 25%
difference with a power of 0.80 and alpha of 0.05. After
evaluating the initial data derived from the increasing
drug concentrations, the experiments were repeated at
the highest concentrations of the drugs (6-TG at 6 uM
and Zeb at 200 uM). Counts were made and compared
at 24 and 48-hour time points.
Apoptosis assay
Apoptosis assay was performed using Apo3/7 HTS assay
kit according to the manufacturer’s (Cell Technology,
Mountain View, CA) instructions. 15,000 cells were loaded
per well in replicates of six for each treatment (control, 1.5
and 6 μM 6-TG and 50 and 200 μM Zeb) in 50 μl media,
followed by addition of the apo HTS assay reagent
containing quenched (z-DEVD)2-R110 dye substrate
(50 μl). This was incubated for 1 h at 37°C. Active
caspase 3/7 R110 cleaved the free dye, which excites at
488 nm, and the emission at 520 nm was read using a
fluorescent plate reader.
Statistical analysis
For cell survival analysis, treatment groups were compared
by ANOVA (GraphPad Prism, GraphPad Software) with
Holm-Sidak pair-wise comparison. One-way ANOVA was
also used to compare methylation status. P-values less
than or equal to 0.05 were considered significant.
Ethics statement
The described experiments were conducted using exist-
ing, immortalized canine cell lines. No humans or verte-
brate animals were used in the described studies.Figure 1 Western blot of DNMT1 expression. This image is a western b
with 1.5 μM or 6 μM 6-TG or 50 μM or 200 μM Zeb concentrations when com
molecular weight. The treated groups had a reduction in intensity of DNM
the expression of DNMT1 treated CLGL 90 cells (6-TG low, high and Zeb low,
control, respectively. Reduction in the expression of DNMT1 treated CLL 17–7
control is Beta-actin.Results
6-TG and zebularine cause downregulation of DNMT1
To determine whether DNMT1 expression is reduced by
6-TG and Zeb treatment of canine cells, western blot
analysis was performed. DNMT1 was reduced when
treated with 6-TG and Zeb in both cell lines (Figure 1).
The basal protein levels of DNMT1 were lower for the
CLL 17–7 cell line than for the CLGL-90 cell line.
6-thioguanine and zebularine globally demethylate
malignant lymphoid cells
Global methylation was analyzed using RLGS, which
produces varying lengths of DNA strands dependent upon
cytosine methylation status. Samples were incubated with
HpaII (methylation-restricted) or MspI (methylation unre-
stricted). Analysis of the resulting electrophoresis gels
demonstrated significant decreases (P < 0.001) in global
methylation following treatment with 6-TG and Zeb
(Figure 2) in both cell lines. This effect was compara-
tively greater in the CLL 17–7 cell line than the CLGL-
90 cell line (Figure 3A and B).
6-thioguanine and zebularine cause a dose-dependent
reduction in cell survival
CLGL-90 cells were plated at 2 × 105 cells per well in 6
well plates. They were treated with either 0 (control),
1.5, 3.0, 6.0 μM 6-TG or 50, 100, 200 μM Zeb at time-
points 0 and 24 hours. Cells were counted at 24 and
48 hours. There was a decrease in cell viability compared
to control following exposure to Zeb at the highest
concentration (P = 0.026) (Figure 4). 6-TG decreased the
surviving fraction in a concentration dependent manner
(P = 0.013) (Figure 5).
Apoptosis
Compared to control samples, treatment with both 6-TG
and Zeb resulted in significantly increased Caspase 3/7
activity (P = 0.0011) (Figure 6). This increase in apoptosis
was not dose-dependent for either drug.lot of DNMT1 protein expression in CLGL 90 and CLL 17–7 cells treated
pared to control. DNMT bands are evident at approximately 180,000
T1 expression as evident by bands in the 180 kDA region. Reduction in
high groups) was 0.81, 0.76, 0.89, and 0.67 when compared to untreated
cells (6-TG and Zeb high dose) is 0.27 and 0.40, respectively. Loading
Figure 2 DNA gel electrophoresis showing endonuclease activity in restriction landmark genomic scanning. Lanes: Lad = ladder, 1 = Control,
2 = Control + Hpa, 3 = Control + Msp, 4 = 6TG, 5 = 6TG + Hpa, 6 = Hpa + Msp, 7 = Zeb, 8 = Zeb + Hpa, 9 = Zeb + Msp. 1 kb pair DNA ladders were
loaded into lane 1, followed by control, HpaII, and MspI incubated extracted DNA from the lymphoma cell line for low and high doses of 6-TG
and Zeb respectively. The MSV equation MSV ¼ DensityHpaII‐ DensityBackgroundDensityMspI‐ DensityBackground
 
was used for each treatment subset. Densities were calculated at the
2.0-2.3 kb pair region. Boxes shown in the first three lanes demonstrate the region of analysis.
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Aberrant DNA methylation represents a novel target in
the management of lymphoid malignancies. Evidence
exists for hypermethylated tumor suppressor genes [18,19]
and global DNA demethylation [17] in canine lymphoma.
However, to date, the mechanism of demethylation by
antimetabolites has not been demonstrated in malignant
canine lymphoid cells.
The anti-metabolite 6-TG was recently shown to have
DNA demethylating properties in a human lymphoma
cell line [21]. With exposure to 6-TG, DNMT1 is shifted
toward ubiquination-mediated proteasomal degradation
via alteration of the expression of histone lysine-specific
demethylase. While this specific mechanism was not con-
firmed in our study, we demonstrated similar decrease in
DNMT1 protein in canine cells. Using western blotting
techniques, we showed that both 6-TG and Zeb decreaseFigure 3 A and B. Relative global DNA methylation with and without
after treatment with 6-TG and Zeb. 6-TG and Zeb had a statistically signific
control for each cell line. All results were normalized to control values of 1
17–7 in panel B. The central bar represents the mean of the data and errorDNMT1 protein in canine malignant lymphoid cells. This
is a critical finding to support clinical application of
demethylation therapy to canine cancers, and the first
report of such a mechanism. Basal levels of DNMT1 were
lower in the CLL 17–7 cell line, but the demethylating
drugs still resulted in decreased protein expression. With
the lower basal levels of this DNA methyltransferase, yet
marked demethylation following treatment, it is possible
that another protein in this family is more important to
maintenance of methylation in this cell line.
The identification of global demethylation relative to
control cells confirms the biologic effect of the decrease
in DNMT1. The selectivity of demethylation by these
agents is unknown. Further work is necessary to identify
the genes and gene classes affected by these drugs. It is
unclear if there is drug selectivity for therapeutically
advantageous gene (i.e. tumor suppressor genes) activation,treatment by 6-TG or zebularine. RLGS global methylation results
ant (P < 0.001) reduction in relative methylation when compared to
for purposes of comparison. CLGL-90 is presented in panel A and CLL
bars represent the standard deviation.
Figure 4 CLGL-90 cell survival at 24 and 48-hour following
treatment high dose 6-TG and zebularine compared to untreated
controls. 6-TG and Zeb were applied at 6 uM and 200 uM respectively.
The number of alive and dead cells was significantly different for
treated groups zebularine (p = 0.026) compared to controls, but not
for 6-TG (p = 0.092). The error bars represent the standard deviation.
Figure 6 Fluorescent intensity of activated Caspase 3/7 assay
following treatment with 6-TG or Zeb. Shown is the absolute
intensity of fluorescence of 15,000 cells evaluated following no
treatment (control) or low or high dose of 6-TG or Zeb. All treated
groups are significantly different from control (P = 0.0011), but there is
no difference between concentrations. The error bars represent the
standard deviation.
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unclear whether proto-oncogenes could become activated,
promoting cells to enter the cell cycle. A potential pit-fall
of this treatment could be tumor promotion if previously
silenced pro-survival, anti-apoptotic, or other “aggressive”
genes are awakened.
Because 6-TG is a purine antimetabolite, with activity
against lymphoproliferative diseases [27,28], we investi-
gated its effect on cell survival in CLGL-90. Both 6-TG
and Zeb have a dose-dependent and cumulative effect
on cell viability. Apoptosis was the mechanism of cell
death, similar to the proposed mechanism of apoptosis
or necrosis in human acute lymphoblastic leukemiaFigure 5 Proportion of cells surviving following 48 hours of
exposure to 6-G or Zeb normalized to controls. Proportion of
viable cells decreased significantly compared to control at 48 hours
(P < 0.001). When comparisons were made inside groups, low vs. high
treated cells showed a dose-dependent response to 6-TG (P = 0.013).
The error bars represent the standard deviation.Molt-4 T-cell treated with 6-TG in vitro [21]. However,
the agents could also impede cell proliferation or cause
cell cycle changes associated with methylation distur-
bances. Zebularine has been shown to be safe in small and
large animal studies [24] with a similar demethylating
mechanism. In vivo effects of Zeb in dogs have yet to be
published, although preliminary evaluation of in vivo
canine safety has been reported (Christopher Fulkerson,
personal communication).
Our group has begun to investigate the strategy of
priming with demethylation therapy immediately prior
to chemotherapy in the relapse-resistant setting. A simi-
lar approach has been investigated in a mouse model of
human diffuse large B cell lymphoma, giving decitabine
prior to doxorubicin and CHOP chemotherapy for
synergistic effect [29]. In immunocompromised mice,
decitabine suppressed xenograft resistant lymphoma
growth. Further, SMAD1, in the family of transforming
growth factor-beta, was shown to be hypermethylated and
silenced in the resistant lymphoma cell lines. Treatment
with decitabine caused reactivation of SMAD1, and
re-sensitization to doxorubicin in vitro. This treatment
(decitabine priming followed by standard chemother-
apy) was then administered to human patients, and
SMAD1 demethylation was shown in lymph node biop-
sies. The phase I clinical trial was safely administered
and showed encouraging complete responses [29].
While this research is encouraging for future canine
lymphoma treatment, it does have its limitations. All
work reported was in vitro. The cell lines selected are
traditional canine lymphoma cell lines, but were recently
re-characterized as lymphoid leukemia cell lines [25].
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normal lymph nodes and in lymphoproliferative disorders
in untreated dogs. We plan to compare this to dogs
receiving standard cytotoxic chemotherapy, with or with-
out the addition of demethylating agents. If global de-
methylation is shown in the clinical model, we will explore
which specific genes, especially tumor suppressor genes,
are affected by methylation. This work does raise the
concern of activating oncogenes, and whether demethy-
lating agents might actually confer a phenotypic advan-
tage to aggressive lymphoma. Tomiyasu and others
compared drug-sensitive canine lymphoma cell lines to
drug-resistant lines. The ABCB1 gene associated with
multi-drug resistance was hypomethylated in the drug-
resistant cell lines [30]. This finding suggests that fur-
ther evaluation of the exact mechanism and effect of
demethylating drugs in tumor-bearing dogs is warranted.
While our research investigates canine lymphoprolifer-
ative disorders, human clinical trials have shown signifi-
cant clinical responses in patients with other, resistant
myeloproliferative disorders (MPD) [16]. While these
drugs have not been investigated prospectively in MPD in
veterinary medicine, the safety of 5-azacitidine (Vidaza), a
demethylating agent, has been demonstrated in dogs
with naturally occurring urothelial carcinoma [31]. Partial
responses or stable disease were seen in the majority of
dogs. Myelosuppression was the primary side effect noted.
We expect the investigation of mechanism of action and
therapeutic utility of epigenetic modifiers in veterinary
medicine to flourish, hopefully leading to increased effi-
cacy and survival when used with current therapies.
Conclusions
These results confirm the demethylating action of 6-TG
and Zeb in canine cells, confirm a similar demethylating
mechanism as that shown in human cell lines, and
support the need for in vivo research to determine
whether these compounds could improve response to
therapy in dogs with resistant lymphoma.
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